Skip to main content

Werewolf Therapeutics, Inc.

HOWL
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001785530

No open-market purchases or sales by Werewolf Therapeutics, Inc. insiders were filed in the last 90 days; 46 institutions reported holding it in 13F filings for Q3 2026, worth $11.9M in total; no superinvestor holds it.

Key figures

Market capClose on Nov 20, 2026
$46.0M
Insider buysOpen market, last 90 days
0
Insider sellsOpen market, last 90 days
0
13F holdersQ3 2026, +1 vs. previous quarter
46
13F valueReported value at the end of Q3 2026
$11.9M
Superinvestors holdingAt the end of Q3 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2025
–
No comparable prior period
Net income, FY2025
-$60.8M
No comparable prior period
Free cash flow, FY2025
-$60.3M
No comparable prior period
Revenue, Q3 FY2026
–
No comparable prior period

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
2.13M
Shares sold short
Change
−227.6K
−9.7% vs. previous
Days to cover
6.39
At average daily volume

Superinvestors holding HOWL, Q3 2026

Go to the superinvestors tab

No superinvestor reported holding HOWL at the end of Q3 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Werewolf Therapeutics, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jul 8, 2026 (view filing)5:34 PM ETJul 6-72 daysEvnin LukeDirectorSSale−143.2K$0.3125−$44.7K−100.0%0 after2 lots10b5-1
Jun 29, 2026 (view filing)7:07 PM ETJun 29Same dayEvnin LukeDirectorSSale−157.1K$0.30−$47.1K−52.3%143.2K after10b5-1
Jun 22, 2026 (view filing)6:59 PM ETJun 175 daysRA Capital Healthcare Fund LP and 3 others10% OwnerSSale−416.9K$0.35−$145.9K−57.9%303.7K after2 lots
Jun 16, 2026 (view filing)6:01 PM ETJun 12-164 daysRA Capital Healthcare Fund LP and 3 others10% OwnerSSale−448.8K$0.3871−$173.8K−57.5%331.4K after6 lots
Jun 11, 2026 (view filing)8:13 PM ETJun 9-112 daysRA Capital Healthcare Fund LP and 3 others10% OwnerSSale−678.2K$0.3739−$253.6K−65.2%361.2K after6 lots
Jun 10, 2026 (view filing)5:20 PM ETJun 91 dayEvnin LukeDirectorSSale−76.9K$0.37−$28.5K−20.4%300.3K after10b5-1
Jun 8, 2026 (view filing)6:13 PM ETJun 4-84 daysEvnin LukeDirectorSSale−105.6K$0.4076−$43.0K−21.9%377.2K after3 lots10b5-1
Jun 3, 2026 (view filing)6:42 PM ETJun 1-32 daysEvnin LukeDirectorSSale−139.8K$0.4551−$63.6K−22.5%482.8K after3 lots10b5-1
May 29, 2026 (view filing)6:51 PM ETMay 27-292 daysEvnin LukeDirectorSSale−141.1K$0.4692−$66.2K−18.5%622.6K after3 lots10b5-1
May 26, 2026 (view filing)6:18 PM ETMay 21-265 daysEvnin LukeDirectorSSale−191.8K$0.4514−$86.6K−20.1%763.7K after3 lots10b5-1

Top 10 13F holders, Q3 2026

See all 46 holders

The largest institutional positions in Werewolf Therapeutics, Inc. at the end of Q3 2026; share changes are against Q2 2026.

Institutions holding HOWL in Q3 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Balyasny Asset Management LLC3,040,251$2.80M0.01%+1,250,162+69.8%Added
ADAR1 Capital Management, LLC2,023,331$1.87M0.08%+2,023,331New
Vanguard Capital Management LLC1,217,976$1.12M0.00%00.0%Unchanged
Lynx1 Capital Management LP657,786$606.7K0.09%00.0%Unchanged
Sphera Funds Management Ltd.626,810$578.1K0.09%00.0%Unchanged
DC Funds, LP589,102$543.3K73.28%00.0%Unchanged
Jane Street Group, LLC564,526$520.7K0.00%+312,689+124.2%Added
Citadel Advisors LLC553,702$510.7K0.00%+553,702New
Renaissance Technologies LLC550,935$508.1K0.00%−123,697−18.3%Reduced
HRT Financial LP415,191$382.0K0.00%+415,191New

Holders of 5% or more of HOWL

See all 2 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Werewolf Therapeutics, Inc..

Largest holders of HOWL from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
Balyasny Asset Management LLC13G6.26%3.04M sharesNewNov 16, 20261 filingNov 16, 2026SEC
Moll Peter13G5.20%2.54M sharesNewSep 21, 20261 filingSep 21, 2026SEC